Renaissance Technologies LLC Cuts Holdings in ANI Pharmaceuticals, Inc. $ANIP

Renaissance Technologies LLC trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 40.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,102 shares of the specialty pharmaceutical company’s stock after selling 128,300 shares during the quarter. Renaissance Technologies LLC’s holdings in ANI Pharmaceuticals were worth $14,311,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, Norges Bank purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $625,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent research reports. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 price target on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Guggenheim reissued a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.00.

Insider Activity

In related news, CEO Nikhil Lalwani sold 55,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the transaction, the chief executive officer directly owned 349,889 shares in the company, valued at approximately $27,140,889.73. This represents a 13.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total transaction of $220,374.00. Following the completion of the sale, the senior vice president directly owned 78,696 shares in the company, valued at $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 88,029 shares of company stock worth $6,954,472 in the last 90 days. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.5%

NASDAQ ANIP opened at $79.24 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average of $81.13 and a two-hundred day moving average of $79.52. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of 20.06 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the business posted $1.70 earnings per share. The business’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.